object
studi
clinic
impact
respiratori
viral
infect
children
cystic
fibrosi
cf
design
retrospect
cohort
studi
set
tertiari
care
referr
centr
cf
india
participantspati
children
cf
attend
pediatr
chest
clinic
method
case
record
children
cf
pulmonari
exacerb
document
acut
respiratori
viral
infect
octob
decemb
group
equal
number
control
group
ii
pulmonari
exacerb
absenc
acut
respiratori
viral
infect
review
outcom
measur
two
group
compar
follow
outcom
period
month
bacteri
colon
antibiot
usag
pulmonari
exacerb
number
outpati
visit
hospit
oxygen
therapi
spirometr
paramet
result
total
children
viral
infect
group
without
viral
infect
group
ii
age
month
enrol
baselin
clinic
statu
pulmonari
function
test
compar
mean
sd
followup
durat
viral
infect
viral
infect
month
respect
followup
children
viral
infect
group
advers
outcom
form
greater
worsen
shwachman
clinic
score
number
pulmonari
exacerb
requir
antibiot
usag
need
intraven
antibiot
vs
hospit
rate
vs
mortal
vs
respect
conclus
acut
viral
infect
children
cf
affect
cours
ill
followup
includ
frequent
sever
pulmonari
exacerb
requir
hospit
intraven
antibiot
declin
cf
score
increas
mortal
next
month
respiratori
failur
major
caus
morbid
mortal
patient
cystic
fibrosi
cf
bacteri
infect
gener
thought
major
caus
clinic
deterior
howev
literatur
suggest
respiratori
virus
play
import
role
pulmonari
exacerb
diseas
progress
increas
bacteri
adher
cf
airway
even
appropri
use
antibiot
therapi
chronic
obstruct
airway
diseas
continu
develop
patient
cf
major
caus
morbid
mortal
children
cf
approxim
half
pulmonari
exacerb
associ
viral
infect
associ
worsen
spirometr
paramet
time
especi
young
children
respiratori
viru
infect
lead
secondari
bacteri
infect
cf
may
implic
manag
cf
henc
conduct
retrospect
cohort
studi
compar
effect
viral
infect
clinic
cours
children
cf
period
month
retrospect
cohort
studi
data
collect
case
record
cf
patient
attend
pediatr
chest
clinic
indian
tertiari
care
centr
cf
diagnos
base
typic
clinic
characterist
two
elev
sweat
chlorid
level
differ
occas
nasopharyng
aspir
nasal
swab
children
cf
present
pulmonari
exacerb
octob
decemb
test
viral
pathogen
use
realtim
polymeras
chain
reaction
pcr
fasttrack
diagnost
luxembourg
part
anoth
studi
done
institut
b
arvind
unpublish
dissert
pcr
test
could
detect
rhino
human
corona
influenza
b
parainfluenza
adeno
respiratori
syncyti
human
metapneumo
echo
virus
children
cf
routin
follow
pediatr
chest
clinic
everi
month
earlier
indic
clinic
inform
record
use
predesign
performa
children
cf
whose
nasopharyng
aspiratesnas
swab
test
found
posit
viral
infect
exacerb
includ
group
children
cf
pulmonari
exacerb
whose
throat
swab
test
neg
viral
pathogen
enrol
control
match
age
sex
group
ii
children
follow
everi
month
earlier
need
detail
followup
visit
month
throat
swab
collect
collect
predesign
performa
includ
follow
age
gender
weight
height
time
throat
swab
collect
followup
bacteri
colon
intraven
oral
antibiot
usag
episod
outpati
visit
hospit
percentag
predict
forc
expiratori
volum
fvc
forc
vital
capac
mmef
maximum
midexpiratori
flow
age
height
clinic
cf
score
clinic
cf
score
design
shwachman
kulczycki
use
assess
clinic
statu
children
followup
assess
pancreat
insuffici
done
histori
frequent
foulsmel
oili
stool
written
inform
consent
taken
parentguardian
collect
respiratori
specimen
viral
detect
earlier
studi
b
arvind
unpublish
dissert
ethic
clearanc
obtain
institut
ethic
committe
current
studi
collect
data
case
record
form
children
cf
routin
follow
pediatr
chest
clinic
institut
consent
retrospect
studi
obtain
parentguardian
data
analys
use
stata
ver
colleg
station
tx
us
signific
differ
variou
paramet
group
ii
examin
use
student
ttest
mannwhitney
test
accord
distribut
paramet
weight
age
height
age
zscore
calcul
use
anthroplu
softwar
geneva
visit
throat
swab
viral
detect
collect
consid
baselin
visit
studi
multivari
analysi
perform
use
perform
logist
regress
model
twentythre
children
cf
includ
group
baselin
characterist
studi
children
compar
group
present
tabl
distribut
virus
detect
respiratori
specimen
enrol
children
shown
intraven
antibiot
usag
episod
hospit
significantli
children
viral
infect
compar
other
mortal
also
significantli
higher
children
viru
detect
compar
viru
could
detect
respiratori
specimen
p
tabl
total
children
group
children
group
could
perform
spirometri
paramet
shown
tabl
seven
children
die
group
rhinoviru
detect
five
adenoviru
one
coronaviru
one
pulmonari
exacerb
evalu
viral
infect
cours
ill
children
infect
rhinoviru
compar
infect
virus
tabl
group
three
patient
newli
colon
pseudomona
aeruginosa
one
patient
colon
betahaemolyt
streptococcu
wherea
group
ii
three
patient
colon
pseudomona
two
patient
colon
staphylococcu
aureu
viru
isol
allerg
bronchopulmonari
aspergillosi
abpa
present
three
children
group
five
children
group
ii
one
patient
home
oxygendepend
retrospect
cohort
studi
demonstr
cf
children
suffer
viral
respiratori
infect
wors
outcom
followup
form
lower
cf
score
higher
use
intraven
antibiot
higher
rate
hospit
higher
mortal
compar
match
control
viral
respiratori
infect
respiratori
virus
associ
respiratori
exacerb
cf
includ
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
type
rhinoviru
human
metapneumoviru
coronaviru
adenoviru
viral
infect
predispos
respiratori
epithelium
secondari
bacteri
infect
multipl
mechan
result
frequent
pulmonari
exacerb
rhinoviru
report
major
viral
pathogen
cf
detect
rate
reach
sampl
collect
exacerb
routin
visit
cohort
rhinoviru
commonli
detect
viru
prospect
multibirth
cohort
studi
armstrong
et
al
viral
infect
infant
cf
infanc
children
hospit
respiratori
distress
viral
infect
conclud
viral
infect
import
caus
hospit
children
cf
abman
et
al
follow
infant
cf
period
month
rang
month
infant
hospit
time
respiratori
distress
among
children
rsv
detect
infant
report
earlier
research
cf
children
document
patient
virusassoci
infect
higher
use
antibiot
longterm
followup
compar
without
virusassoci
respiratori
tract
infect
cohort
usag
oral
antibiot
similar
group
requir
intraven
antibiot
significantli
higher
followup
cf
patient
viral
respiratori
infect
compar
viru
detect
respiratori
specimen
vs
p
cf
patient
viral
infect
children
requir
hospit
pulmonari
exacerb
followup
period
wherea
patient
group
requir
hospit
admiss
hospit
higher
cf
children
rhinoviru
detect
compar
viru
decad
presum
virus
may
harbing
infect
typic
bacteri
cf
pathogen
tempor
link
propos
viral
infect
new
pseudomona
infect
current
limit
data
avail
determin
effect
viral
infect
cf
lung
microbiota
vitro
studi
shown
rsv
influenza
viru
increas
adher
pseudomona
human
airway
also
shown
rsv
promot
growth
pseudomona
biofilm
modul
immun
respons
pathogen
iron
metabol
rhinoviru
promot
free
movement
pseudomona
biofilm
contrast
believ
recent
studi
dynam
interact
respiratori
virus
lung
microbiota
children
recent
report
viral
infect
impact
bacteri
divers
cohort
three
children
group
found
new
pseudomona
infect
followup
suggest
viral
infect
may
factor
involv
colon
pseudomona
airway
epithelium
cf
children
viral
infect
cf
patient
associ
declin
pulmonari
function
major
studi
shown
declin
trend
fvc
longterm
followup
cf
patient
virusassoci
lower
respiratori
tract
infect
studi
like
ramsey
et
al
show
effect
pulmonari
function
test
vital
capac
vc
residu
volum
rv
total
lung
capac
tlc
followup
children
cf
viral
infect
recent
review
clinic
impact
respiratori
virus
cf
suggest
high
burden
viral
respiratori
infect
children
cf
like
link
progress
cf
lung
diseas
cohort
group
shown
decrement
lung
function
test
followup
period
decrement
group
though
statist
signific
suggest
lung
diseas
progress
period
time
patient
irrespect
viral
infect
diseas
progress
cf
assess
clinic
data
chest
radiographi
tomographi
pulmonari
function
test
shwachmankulczycki
sk
score
commonli
use
score
follow
progress
diseas
activ
cf
children
review
clinic
data
gener
activ
physic
examin
nutrit
cohort
baselin
group
compar
said
three
domain
howev
last
visit
children
group
poorer
score
domain
gener
activ
physic
examin
nutrit
compar
group
ii
suggest
viral
infect
may
play
role
worsen
clinic
statu
children
cf
nevertheless
subject
score
need
kept
mind
apart
morbid
cf
caus
pulmonari
exacerb
annual
number
exacerb
consider
impact
surviv
also
cohort
mortal
constitut
group
viral
infect
attribut
sever
pulmonari
exacerb
requir
hospit
group
children
total
children
requir
hospit
group
cf
viral
respiratori
infect
die
end
followup
period
predict
model
cf
patient
requir
hospit
twice
year
time
like
die
within
year
similar
surviv
predict
model
compris
data
cf
patient
select
cystic
fibrosi
foundat
patient
registri
acut
pulmonari
exacerb
within
first
year
followup
increas
risk
death
time
follow
year
prospect
cohort
studi
conduct
adult
cf
patient
two
exacerb
per
year
greater
risk
lung
transplant
death
studi
less
one
exacerb
per
year
adjust
hazard
ratio
patient
least
moder
pancreat
insuffici
suggest
presenc
histori
frequent
foulsmel
oili
stool
also
note
patient
malnourish
baselin
group
along
low
might
contribut
high
mortal
part
support
care
apart
antibiot
pulmonari
exacerb
play
import
role
care
cf
patient
clinic
advis
demonstr
regard
chest
physiotherapi
inhal
therapi
hyperton
salin
salin
daili
enzym
replac
therapi
howev
routin
use
dnase
potenti
corrector
cost
constraint
also
want
highlight
fact
patient
pancreat
insuffici
patient
milder
diseas
suspect
cf
lack
awar
belief
cf
occur
indian
children
strength
studi
includ
use
highli
sensit
assay
detect
viru
longterm
followup
month
indian
children
cf
major
limit
studi
retrospect
design
determin
viral
aetiolog
pulmonari
exacerb
done
enrol
subsequ
exacerb
investig
viral
etiolog
c
n
c
l
u
n
follow
viral
respiratori
infect
children
cf
alreadi
nutrit
compromis
frequent
sever
pulmonari
exacerb
requir
hospit
intraven
antibiot
declin
cf
score
increas
mortal
next
month
